alexa Formulation And Characterization Of Piribedil Buccal Tablets
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

9th Annual European Pharma Congress
June 26-28, 2017 Madrid, Spain

Burak Celik and Melike Uner
Bezmialem Vakıf University, Turkey
Istanbul University, Turkey
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689-C1-025
Piribedil is a piperazin derivative drug used in the treatment of Parkinson’s disease. Orally administrated piribedil has low bioavailability (10%) accompanied with gastrointestinal and cognitive side effects. Buccal tablets are thin and flat tablets with 5-8 mm diameter which are applied to the oral mucosa in the mouth cavity. This route of administration increases bioavailability of drugs by eliminating the hepatic first pass effect and reduces side effect risks with controlled release by lowering the required dosage. In this study, buccal tablets were prepared by using three different polymers; carbopol (CP), hydroxypropyl methylcellulose (HPMC) and carboxymethyl cellulose (CMC) at three different concentrations to achieve controlled release. Physicochemical properties of powder and tablet formulations were investigated and dissolution studies were conducted. These tablets were also subjected to stability studies for 6 months at 40±2oC and 75±5% relative humidity. Physical characterization results were satisfactory and met compendial limits for all formulations. Slowest drug release was observed with CP followed by HPMC and CMC respectively. Drug release kinetics displayed diffusion-polymer relaxation for CP and HPMC and diffusion-tablet erosion for CMC tablets. Piribedil was found to be compatible with other tablet ingredients and tablets retained physical properties after 6 months of stability studies. Buccal tablets containing piribedil designed for the first time may serve as a new alternative for the Parkinson’s disease treatment.

Burak Çelik has completed his graduation from Faculty of Pharmacy at Yeditepe University and PhD from Istanbul University, Department of Pharmaceutical Technology. He is currently working at Bezmialem Vakıf University, Faculty of Pharmacy as a Research Assistant.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version